Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 98

1.

Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer.

Gulley JL, Madan RA, Tsang KY, Jochems C, Marté JL, Farsaci B, Tucker JA, Hodge JW, Liewehr DJ, Steinberg SM, Heery CR, Schlom J.

Cancer Immunol Res. 2014 Feb;2(2):133-41. doi: 10.1158/2326-6066.CIR-13-0108. Epub 2013 Nov 4.

PMID:
24778277
[PubMed - in process]
2.

A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer.

DiPaola RS, Plante M, Kaufman H, Petrylak DP, Israeli R, Lattime E, Manson K, Schuetz T.

J Transl Med. 2006 Jan 3;4:1.

PMID:
16390546
[PubMed]
Free PMC Article
3.

Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer.

Gulley JL, Heery CR, Madan RA, Walter BA, Merino MJ, Dahut WL, Tsang KY, Schlom J, Pinto PA.

Cancer Immunol Immunother. 2013 Sep;62(9):1521-31. doi: 10.1007/s00262-013-1448-0. Epub 2013 Jul 9.

PMID:
23836412
[PubMed - indexed for MEDLINE]
4.

Identification by digital immunohistochemistry of intratumoral changes of immune infiltrates after vaccine in the absence of modifications of PBMC immune cell subsets.

Farsaci B, Jochems C, Grenga I, Donahue RN, Tucker JA, Pinto PA, Merino MJ, Heery CR, Madan RA, Gulley JL, Schlom J.

Int J Cancer. 2014 Aug 15;135(4):862-70. doi: 10.1002/ijc.28743. Epub 2014 Feb 22.

PMID:
24474335
[PubMed - indexed for MEDLINE]
5.

Vaccine therapy of established tumors in the absence of autoimmunity.

Hodge JW, Grosenbach DW, Aarts WM, Poole DJ, Schlom J.

Clin Cancer Res. 2003 May;9(5):1837-49.

PMID:
12738742
[PubMed - indexed for MEDLINE]
Free Article
6.

Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer.

Madan RA, Arlen PM, Mohebtash M, Hodge JW, Gulley JL.

Expert Opin Investig Drugs. 2009 Jul;18(7):1001-11. doi: 10.1517/13543780902997928. Review.

PMID:
19548854
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.

Aarts WM, Schlom J, Hodge JW.

Cancer Res. 2002 Oct 15;62(20):5770-7.

PMID:
12384537
[PubMed - indexed for MEDLINE]
Free Article
8.

Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer.

Sanda MG, Smith DC, Charles LG, Hwang C, Pienta KJ, Schlom J, Milenic D, Panicali D, Montie JE.

Urology. 1999 Feb;53(2):260-6.

PMID:
9933036
[PubMed - indexed for MEDLINE]
9.

A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.

Arlen PM, Gulley JL, Parker C, Skarupa L, Pazdur M, Panicali D, Beetham P, Tsang KY, Grosenbach DW, Feldman J, Steinberg SM, Jones E, Chen C, Marte J, Schlom J, Dahut W.

Clin Cancer Res. 2006 Feb 15;12(4):1260-9.

PMID:
16489082
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

A cytomegalovirus-based vaccine expressing a single tumor-specific CD8+ T-cell epitope delays tumor growth in a murine model of prostate cancer.

Klyushnenkova EN, Kouiavskaia DV, Parkins CJ, Caposio P, Botto S, Alexander RB, Jarvis MA.

J Immunother. 2012 Jun;35(5):390-9. doi: 10.1097/CJI.0b013e3182585d50.

PMID:
22576344
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Clinical evaluation of TRICOM vector therapeutic cancer vaccines.

Madan RA, Bilusic M, Heery C, Schlom J, Gulley JL.

Semin Oncol. 2012 Jun;39(3):296-304. doi: 10.1053/j.seminoncol.2012.02.010. Review.

PMID:
22595052
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.

Karan D, Dubey S, Van Veldhuizen P, Holzbeierlein JM, Tawfik O, Thrasher JB.

Immunotherapy. 2011 Jun;3(6):735-46. doi: 10.2217/imt.11.59.

PMID:
21668311
[PubMed - indexed for MEDLINE]
13.

CD4 and CD8 T-lymphocyte recognition of prostate specific antigen in granulomatous prostatitis.

Klyushnenkova EN, Ponniah S, Rodriguez A, Kodak J, Mann DL, Langerman A, Nishimura MI, Alexander RB.

J Immunother. 2004 Mar-Apr;27(2):136-46.

PMID:
14770085
[PubMed - indexed for MEDLINE]
14.

Evidence of determinant spreading in the antibody responses to prostate cell surface antigens in patients immunized with prostate-specific antigen.

Cavacini LA, Duval M, Eder JP, Posner MR.

Clin Cancer Res. 2002 Feb;8(2):368-73.

PMID:
11839651
[PubMed - indexed for MEDLINE]
Free Article
15.

Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.

Gulley JL, Arlen PM, Bastian A, Morin S, Marte J, Beetham P, Tsang KY, Yokokawa J, Hodge JW, Ménard C, Camphausen K, Coleman CN, Sullivan F, Steinberg SM, Schlom J, Dahut W.

Clin Cancer Res. 2005 May 1;11(9):3353-62. Erratum in: Clin Cancer Res. 2006 Jan 1;12(1):322.

PMID:
15867235
[PubMed - indexed for MEDLINE]
Free Article
16.

Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects.

Grosenbach DW, Barrientos JC, Schlom J, Hodge JW.

Cancer Res. 2001 Jun 1;61(11):4497-505.

PMID:
11389081
[PubMed - indexed for MEDLINE]
Free Article
17.

Drug evaluation: Therion's rV-PSA-TRICOM + rF-PSA-TRICOM prime-boost prostate cancer vaccine.

Doehn C, Kausch I, Böhmer T, Sommerauer M, Jocham D.

Curr Opin Mol Ther. 2007 Apr;9(2):183-9.

PMID:
17458173
[PubMed - indexed for MEDLINE]
18.

Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine.

Kim JJ, Trivedi NN, Wilson DM, Mahalingam S, Morrison L, Tsai A, Chattergoon MA, Dang K, Patel M, Ahn L, Boyer JD, Chalian AA, Schoemaker H, Kieber-Emmons T, Agadjanyan MA, Weiner DB.

Oncogene. 1998 Dec 17;17(24):3125-35. Erratum in: Oncogene 1999 Apr 8;18(14):2411. Shoemaker H [corrected to Schoemaker H].

PMID:
9872328
[PubMed - indexed for MEDLINE]
Free Article
19.

A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols.

Lundberg K, Roos AK, Pavlenko M, Leder C, Wehrum D, Guevara-Patiño J, Andersen RS, Pisa P.

Vaccine. 2009 Mar 4;27(10):1557-65. doi: 10.1016/j.vaccine.2009.01.011. Epub 2009 Jan 24.

PMID:
19171173
[PubMed - indexed for MEDLINE]
20.

Induction of Th1-type immunity and tumor protection with a prostate-specific antigen DNA vaccine.

Marshall DJ, San Mateo LR, Rudnick KA, McCarthy SG, Harris MC, McCauley C, Schantz A, Geng D, Cawood P, Snyder LA.

Cancer Immunol Immunother. 2005 Nov;54(11):1082-94. Epub 2005 Jul 27.

PMID:
16047142
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk